A detailed history of China Universal Asset Management Co., Ltd. transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 32,127 shares of RVMD stock, worth $1.39 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
32,127
Previous 19,383 65.75%
Holding current value
$1.39 Million
Previous $752,000 93.48%
% of portfolio
0.16%
Previous 0.11%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$36.92 - $47.94 $470,508 - $610,947
12,744 Added 65.75%
32,127 $1.46 Million
Q2 2024

Jul 19, 2024

SELL
$30.14 - $40.68 $369,335 - $498,492
-12,254 Reduced 38.73%
19,383 $752,000
Q1 2024

Apr 29, 2024

BUY
$26.56 - $33.55 $337,205 - $425,950
12,696 Added 67.03%
31,637 $1.02 Million
Q4 2023

May 21, 2024

SELL
$18.35 - $34.12 $232,971 - $433,187
-12,696 Reduced 40.13%
18,941 $543,000
Q4 2023

Jan 23, 2024

BUY
$18.35 - $34.12 $296,150 - $550,662
16,139 Added 575.98%
18,941 $543,000
Q3 2023

May 21, 2024

BUY
$25.17 - $35.05 $35,464 - $49,385
1,409 Added 101.15%
2,802 $77,000
Q3 2023

Oct 30, 2023

BUY
$25.17 - $35.05 $35,464 - $49,385
1,409 Added 101.15%
2,802 $78,000
Q2 2023

May 21, 2024

BUY
$20.28 - $27.0 $3,386 - $4,509
167 Added 13.62%
1,393 $37,000
Q2 2023

Jul 27, 2023

BUY
$20.28 - $27.0 $3,386 - $4,509
167 Added 13.62%
1,393 $37,000
Q1 2023

May 21, 2024

BUY
$20.76 - $30.09 $6,726 - $9,749
324 Added 35.92%
1,226 $26,000
Q1 2023

Apr 27, 2023

BUY
$20.76 - $30.09 $6,726 - $9,749
324 Added 35.92%
1,226 $27,000
Q4 2022

May 21, 2024

SELL
$17.68 - $25.53 $543,394 - $784,664
-30,735 Reduced 97.15%
902 $21,000
Q4 2022

Jan 31, 2023

BUY
$17.68 - $25.53 $1,432 - $2,067
81 Added 9.87%
902 $21,000
Q3 2022

Oct 21, 2022

BUY
$17.46 - $26.0 $14,334 - $21,346
821 New
821 $16,000

Others Institutions Holding RVMD

About Revolution Medicines, Inc.


  • Ticker RVMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,697,600
  • Market Cap $3.8B
  • Description
  • Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...
More about RVMD
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.